Covaxin, Bharat Biotech's COVID-19 vaccine, is effective against multiple coronavirus variants, including the double mutant strain, according to a study by the Indian Council of Medical Research (ICMR).
"ICMR study shows COVAXIN neutralises against multiple variants of SARS-CoV-2 and effectively neutralises the double mutant strain as well," ICMR said in a tweet.
Also read: Bharat Biotech Covaxin demonstrates 78% efficacy in Phase-3 interim analysisCovaxin has been developed by Hyderabad-based Bharat Biotech in collaboration with the ICMR-National Institute of Virology.
ICMR study shows #COVAXIN neutralises against multiple variants of SARS-CoV-2 and effectively neutralises the double mutant strain as well. @MoHFW_INDIA@DeptHealthRes#IndiaFightsCOVID19#LargestVaccineDrivepic.twitter.com/syv5T8eHuR— ICMR (@ICMRDELHI) April 21, 2021
ICMR-NIV has successfully isolated and cultured multiple variants of concern of SARS-CoV-2 virus - B.1.1.7 (the UK variant), B.1.1.28 (Brazil variant ) and B.1.351 (South Africa variant).
ICMR-NIV has demonstrated the neutralisation potential of Covaxin against the UK variant and Brazil variants, the apex health research body said.
In a subsequent statement, Bharat Biotech said phase 3 interim analysis results of Covaxin demonstrated that the vaccine has 78 percent efficacy.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.